Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 2
1967 2
1969 1
1970 3
1971 6
1972 6
1973 7
1974 4
1975 2
1976 3
1977 2
1978 3
1979 2
1980 4
1981 2
1982 7
1983 3
1984 3
1985 4
1986 8
1987 5
1988 3
1989 7
1990 9
1991 9
1992 11
1993 8
1994 15
1995 17
1996 11
1997 12
1998 12
1999 19
2000 21
2001 17
2002 25
2003 14
2004 27
2005 33
2006 36
2007 30
2008 32
2009 44
2010 37
2011 51
2012 61
2013 66
2014 78
2015 79
2016 79
2017 78
2018 87
2019 103
2020 137
2021 139
2022 113
2023 114
2024 98
2025 98
2026 51

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,738 results

Results by year

Filters applied: . Clear all
Page 1
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Armstrong AW, et al. Among authors: morita a. J Am Acad Dermatol. 2023 Jan;88(1):29-39. doi: 10.1016/j.jaad.2022.07.002. Epub 2022 Jul 9. J Am Acad Dermatol. 2023. PMID: 35820547 Free article. Clinical Trial.
Evidence-based consensus on the clinical application of photobiomodulation.
Maghfour J, Mineroff J, Ozog DM, Jagdeo J, Lim HW, Kohli I, Anderson R, Kelly KM, Mamalis A, Munavalli G, Cleber F, Siegel D, Geneva I, Weiss R, Morita A, Juanita A, Goldman MP, Arany PR, Sliney D, Ibrahimi OA, Chopp M, Esmat S, Tuner J. Maghfour J, et al. Among authors: morita a. J Am Acad Dermatol. 2025 Aug;93(2):429-443. doi: 10.1016/j.jaad.2025.04.031. Epub 2025 Apr 17. J Am Acad Dermatol. 2025. PMID: 40253006 Free article.
Trial of Spesolimab for Generalized Pustular Psoriasis.
Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Navarini AA, Zheng M, Xu J, Turki H, Anadkat MJ, Rajeswari S, Hua H, Vulcu SD, Hall D, Tetzlaff K, Thoma C, Lebwohl MG; Effisayil 1 Trial Investigators. Bachelez H, et al. Among authors: morita a. N Engl J Med. 2021 Dec 23;385(26):2431-2440. doi: 10.1056/NEJMoa2111563. N Engl J Med. 2021. PMID: 34936739 Free article. Clinical Trial.
Asia-Pacific consensus recommendations on the management of generalized pustular psoriasis.
Choon SE, Foley PA, Asawanonda P, Fujita H, Jo SJ, Shi YL, Theng C, Affandi AM, Bang CH, Frez ML, Huei HY, Le Huu D, Kim TG, Morita A, Oon HH, Fernández-Peñas P, Rajatanavin N, Robinson S, Selvarajah L, Tsai TF. Choon SE, et al. Among authors: morita a. J Dermatol. 2024 Dec;51(12):1579-1595. doi: 10.1111/1346-8138.17471. Epub 2024 Oct 10. J Dermatol. 2024. PMID: 39390737 Free PMC article.
International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council.
Choon SE, van de Kerkhof P, Gudjonsson JE, de la Cruz C, Barker J, Morita A, Romiti R, Affandi AM, Asawanonda P, Burden AD, Gonzalez C, Marrakchi S, Mowla MR, Okubo Y, Oon HH, Terui T, Tsai TF, Callis-Duffin K, Fujita H, Jo SJ, Merola J, Mrowietz U, Puig L, Thaçi D, Velásquez M, Augustin M, El Sayed M, Navarini AA, Pink A, Prinz J, Turki H, Magalhães R, Capon F, Bachelez H; IPC Pustular Psoriasis Working Group. Choon SE, et al. Among authors: morita a. JAMA Dermatol. 2024 Jul 1;160(7):758-768. doi: 10.1001/jamadermatol.2024.0915. JAMA Dermatol. 2024. PMID: 38691347
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, Tsai TF, Gordon KB, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl MG. Morita A, et al. Lancet. 2023 Oct 28;402(10412):1541-1551. doi: 10.1016/S0140-6736(23)01378-8. Epub 2023 Sep 19. Lancet. 2023. PMID: 37738999 Clinical Trial.
DOCK2 is involved in the host genetics and biology of severe COVID-19.
Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T, Okudela K, Okuzaki D, Motooka D, Kanai M, Naito T, Yamamoto K, Wang QS, Saiki R, Ishihara R, Matsubara Y, Hamamoto J, Hayashi H, Yoshimura Y, Tachikawa N, Yanagita E, Hyugaji T, Shimizu E, Katayama K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Aoki R, Nakamura A, Harada S, Sasano H, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagi… See abstract for full author list ➔ Namkoong H, et al. Among authors: morita a. Nature. 2022 Sep;609(7928):754-760. doi: 10.1038/s41586-022-05163-5. Epub 2022 Aug 8. Nature. 2022. PMID: 35940203 Free PMC article.
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial.
Blauvelt A, Langley RG, Lebwohl M, Strober B, Warren RB, Puig L, Morita A, Gordon KB, Fernandez-Peñas P, Kavanagh S, López Pinto JM, Lambert J, Hoepken B, Deherder D, Cross N, Thaçi D. Blauvelt A, et al. Among authors: morita a. J Am Acad Dermatol. 2025 Sep;93(3):644-653. doi: 10.1016/j.jaad.2025.04.038. Epub 2025 Apr 24. J Am Acad Dermatol. 2025. PMID: 40286813 Free article. Clinical Trial.
1,738 results